El Salvador first-in-human cost and timeline vs the United States

Boards keep asking how much a first-in-human medical device trial in El Salvador costs compared with the United States, and how long startup actually takes. Those are two questions. One is a published country clock. The other is a study-specific quote. Mixing them into one invented total is how diligence slides go soft.

I am Julio Martinez-Clark, CEO of bioaccess®. This is an El Salvador country spotlight grounded in the live clinical trials in El Salvador hub, the fast-track FIH corridor post, and the sibling cost page that already covers Panama and El Salvador together. It is not a quote. Confirm budgets and calendars against your protocol.

What “vs the United States” usually buys

When sponsors say a U.S. FIH is too expensive, they usually mean three stacked costs:

Time to first patient — site contracting, IRB sequencing, and treating first implant as a United States-only problem.
Site and per-patient economics — hospital fees, investigator fees, and visit complexity priced from the schedule of events.
Evidence quality for later FDA use — ISO 14155 discipline and a 21 CFR § 812.28 design, or you bought speed you cannot spend.

An El Salvador investigation is not a discount coupon on FDA clearance. It is a second evidence calendar that can run while the U.S. path is still being built. Eligibility of foreign data for FDA submission and review is not a guarantee of clearance or approval.

Published El Salvador clocks (investigation only)

The live El Salvador hub already publishes a 30–60 day study-startup band via parallel review by the Superintendencia de Regulación Sanitaria (SRS) and the Comité Nacional de Ética de la Investigación en Salud (CNEIS) on one digital platform. That band is investigation authorization plus ethics — not commercial registro.

SRS replaced the former Dirección Nacional de Medicamentos (DNM) in August 2024 under the Ley de la Superintendencia de Regulación Sanitaria (7 August 2024). Ethics stays centralized at CNEIS. The live step-by-step FIH guide already names the SRS-CNEIS-ES digital platform and the user manual issued 17 November 2025. Use that manual. Do not invent article numbers from reforms you have not opened.

On the corridor clock published in the startup guide, El Salvador sits with Panama, Chile, and Costa Rica in the 15–45 day activation tier for the fast corridor as a whole. Treat those as indicative operator bands. Ask for a study-specific calendar before you put a single date on a board slide.

Cost: what is published vs what must be quoted

Two cost facts already live on bioaccess® pages — and that is where I stop inventing:

The El Salvador hub already publishes roughly 60% cost savings versus equivalent U.S. programs, plus a dollarized (U.S. dollar) economy. That is orientation from the country page, not a formal study for your Class III implant.
Inside the fast corridor, El Salvador is the cost leader on hospital and site fees versus Panama. The corridor post states that gap in plain operator language. Panama remains the proven sprinter on activation; El Salvador undercuts it on site economics.

I will not invent a dollar program total, a weekly burn, or a “typical U.S. per-patient” figure on this page. If your U.S. sites have not returned real bids, leave that cell blank. Blank is more honest than a blogger’s invented average. For how LATAM FIH money actually splits — site pass-throughs, CRO professional fees, third-party costs — start from the FIH Latin America budget guide.

What drives cost and time in El Salvador

Same four stages as the rest of the region; El Salvador compresses them when the file is clean:

Preparation and Spanish package. Protocol, investigator’s brochure, informed consent, case report forms, and the insurance certificate the committee will stamp. Rework, not review, is the usual delay.
CNEIS cadence. Centralized national ethics, not a tourism of local IRBs.
SRS investigation authorization. Parallel with ethics on the published digital path — not a sequential hope.
Investigational import. Units for research only. Do not put a cousin commercial registro number on FIH freight. That pattern burns weeks at customs and contaminates both tracks.

Enrollment is a separate model. El Salvador is a small market. Activation in weeks means nothing if patient flow for your indication is thin. Model enrollment from real San Salvador site flow, prequalify backup sites, and keep the startup clock distinct from first-patient-in.

Keep the trial file off the commercial holder track

Cost discipline in El Salvador starts with two dossiers:

Trial file: Spanish protocol package, CNEIS ethics, SRS investigation authorization, investigational labeling, ISO 14155 monitoring plan, import story for study units only.
Registro / holder file (optional, later): commercial market access. Different petition. Different success criteria. Already spelled out on CNEIS/SRS trial authorization vs registro.

If the same person owns both without two importers and two success criteria, you do not have an El Salvador plan. You have a hope that erases the calendar advantage the hub already publishes.

Insurance and import are line items, not footnotes

Ethics packets still want financial responsibility for participant injury documented before initiation — usually a Spanish certificate. Product liability is not clinical-trial liability. A U.S. master that never names El Salvador fails the exhibit. Budget the certificate with the CRO and a licensed broker before you present “LATAM is cheaper.” See the insurance hub and the language intercept on Spanish/Portuguese certificates.

Public case work already on the site (including Avantec Vascular / Sangria™) treated insurance placement and investigational import as operational workstreams — not as bioaccess® underwriting. We do not invent premiums from those pages.

Colombia note (do not flip the public line)

Colombia remains a strong market-access geography and a historical FIH geography for bioaccess®. The public line still stands: INVIMA clinical-trial approval timelines have become unpredictable, so bioaccess® does not currently recommend Colombia for new first-in-human execution. Use El Salvador, Panama, Chile, or the Dominican Republic when the protocol needs a lead investigation desk — and keep INVIMA registro on the commercial track.

Board slide that survives diligence

Evidence column. El Salvador CNEIS/SRS, investigational importer, § 812.28 owner, ISO 14155 TMF owner.
Published bands only. 30–60 day startup; corridor cost-leader note vs Panama; ~60% vs U.S. orientation from the hub — then a study-specific quote.
U.S. column as real bids — or blank.
Commercial column (optional). Holder / IOR countries on the market-access track. Already-cleared launch is a different SKU from FIH.

Frequently asked questions

How much does a first-in-human medical device trial in El Salvador cost compared with the United States?

Use published orientation, not an invented total. The El Salvador hub already cites roughly 60% cost savings versus equivalent U.S. programs and a dollarized economy. Inside the fast corridor, hospital and site fees run below Panama’s. Program totals still need a proposal priced from your schedule of events. Leave any U.S. comparator blank until named U.S. sites return real bids.

How long does El Salvador FIH startup take?

The country hub publishes 30–60 days via parallel SRS and CNEIS review. The regional startup clock groups El Salvador with the fast corridor at a 15–45 day activation tier. Confirm a study-specific calendar. Activation is not first-patient-in.

Is El Salvador cheaper than Panama for FIH?

On hospital and site fees, yes in bioaccess® operator experience — that is why the corridor post calls El Salvador the cost leader. Panama remains the documented extreme on activation speed. Pick on indication fit and patient flow, not the clock alone.

Is the trial authorization the same as DNM/SRS registro?

No. Investigation and commercial registro are separate files. Merging them creates rework that erases the published calendar advantage.

Does the FDA accept clinical data from El Salvador?

Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets the GCP conditions in that rule, including SRS authorization and CNEIS ethics approval. Eligibility is not clearance or approval.